MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
22 mars 2023 13h22 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
23 févr. 2023 08h01 HE
|
Ocean Biomedical, Inc.
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and...
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
11 oct. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
28 juil. 2022 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
06 juil. 2022 08h00 HE
|
Coherus BioSciences, Inc.
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY,...
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
02 mai 2022 07h00 HE
|
Coherus BioSciences, Inc.
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - -...
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
14 avr. 2022 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”,...
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
08 avr. 2022 13h10 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting
08 avr. 2022 13h01 HE
|
Compass Therapeutics
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to...
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
29 mars 2022 09h15 HE
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...